Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
Grafting of catecholamine-producing cells can be a possible therapeutic strategy for attenuating motor symptoms in Parkinson's disease (PD). The potential of autologous sympathetic neurons has been investigated as a donor for cell therapy of PD. The clinical trials of autotransplantation of sympathetic ganglion cells in PD have revealed that the grafts increase the duration of L-DOPA (L-dihydroxy phenyl alanine)-induced beneficial effects, and that the graft-mediated effect is detectable during a follow-up period of at least 1 year postgrafting. In an in vitro analysis of the ability of human sympathetic neurons to release catecholamines, although DA was not detectable under basal conditions, DA levels were significantly increased upon exposure to exogenous L-DOPA. Furthermore, animal experiments with xenografting of human sympathetic ganglionic neurons in the DA-denervated striatum of rats demonstrated that a significant increase in striatal DA levels is noted after systemic L-DOPA treatment, and that the DA levels remain high for longer periods of time in the grafted rats than in control animals with sham surgery. The L-DOPA-induced rise of striatal DA levels was significantly attenuated when given reserpine pretreatment. This suggests that DA derived from exogenously administered L-DOPA is subjected to, at least in part, vesicular storage in grafted sympathetic neurons. Histological examinations indeed showed that the grafts express aromatic-L-amino acid decarboxylase and vesicular monoamine transporter-2, both of which are important molecules for the synthesis and the storage of DA, respectively. Taken together, grafted sympathetic neurons can provide a site for both the conversion of exogenous L-DOPA to DA and the storage of the synthesized DA in the DA-denervated striatum. This might be an explanation for a mechanism by which sympathetic neuron autografts can increase the duration of L-DOPA effects in PD patients. This review article summarizes the clinical effect of transplantation of autologous sympathetic neurons in PD and discusses the underlying mechanism for the effect based on experimental evidence previously obtained.
Nakao
Naoyuki
N
Department of Neurological Surgery, Wakayama Medical University, Wakayama 641-0012, Japan. nnakao@wakayama-med.ac.jp
Shintani-Mizushima
Aki
A
Kakishita
Koji
K
Itakura
Toru
T
D000818:Animals; D001142:Aromatic-L-Amino-Acid Decarboxylases / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism* / Q000503:physiopathology / Q000601:surgery; D004298:Dopamine / Q000378:metabolism*; D005728:Ganglia, Sympathetic / Q000166:cytology / Q000378:metabolism / Q000637:transplantation*; D006801:Humans; D007980:Levodopa / Q000378:metabolism / Q000627:therapeutic use; D009474:Neurons / Q000166:cytology / Q000378:metabolism / Q000637:transplantation*; D010300:Parkinson Disease / Q000628:therapy*; D017729:Presynaptic Terminals / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism / Q000503:physiopathology; D014182:Transplantation, Autologous; D050493:Vesicular Monoamine Transport Proteins / Q000378:metabolism
D050493:Vesicular Monoamine Transport Proteins; D007980:Levodopa; D001142:Aromatic-L-Amino-Acid Decarboxylases; D004298:Dopamine